WP
CERE

Woodline Partners’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Woodline Partners’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-335,500
Closed -$13.7M – 742
2024
Q2 		$13.7M Sell
335,500
-264,501
-44% -$11M 0.13% 212
2024
Q1 		$25.4M Buy
600,001
+394,192
+192% +$16.6M 0.23% 139
2023
Q4 		$8.73M Sell
205,809
-270,825
-57% -$7.78M 0.09% 244
2023
Q3 		$10.4M Sell
476,634
-318,285
-40% -$7.96M 0.12% 218
2023
Q2 		$25.3M Buy
794,919
+183,553
+30% +$5.63M 0.3% 100
2023
Q1 		$14.9M Buy
611,366
+146,958
+32% +$4.31M 0.2% 145
2022
Q4 		$14.6M Sell
464,408
-71,977
-13% -$2.03M 0.2% 152
2022
Q3 		$15.2M Buy
536,385
+280,852
+110% +$8.36M 0.21% 142
2022
Q2 		$6.76M Sell
255,533
-106,220
-29% -$3.02M 0.1% 218
2022
Q1 		$12.7M Buy
361,753
+124,427
+52% +$3.63M 0.21% 152
2021
Q4 		$7.69M Buy
237,326
+41,995
+21% +$1.48M 0.11% 229
2021
Q3 		$5.76M Buy
195,331
+51,619
+36% +$1.45M 0.09% 235
2021
Q2 		$3.68M Sell
143,712
-249,198
-63% -$3.57M 0.07% 264
2021
Q1 		$5.39M Buy
+392,910
New +$5.75M 0.12% 185

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Woodline Partners's CERE Position: Q3 2024 in Review

Woodline Partners sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 335,500 shares — an estimated $13.7M sold.

Woodline Partners first reported a position in CERE in Q1 2021 and held it in 14 quarters. The position peaked at $25.4M in Q1 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Woodline Partners reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Woodline Partners sold 335,500 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $13.7M.
  • Woodline Partners first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2021 and held it in 14 quarters.
  • Woodline Partners's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $25.4M in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Woodline Partners's 13F filing for Q3 2024, filed 14 Nov 2024.